-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5

Benzinga·07/30/2026 13:35:54
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $62 to $3.5.